Total Payments
$297,458
2024 Payments
$20,345
Companies
52
Transactions
347
Medicare Patients
9,378
Medicare Billing
$11.5M
Payment Breakdown by Category
Other$120,409 (40.5%)
Research$89,940 (30.2%)
Consulting$62,642 (21.1%)
Travel$15,006 (5.0%)
Food & Beverage$9,233 (3.1%)
Education$229.05 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $115,809 | 43 | 38.9% |
| Unspecified | $89,940 | 15 | 30.2% |
| Consulting Fee | $62,642 | 28 | 21.1% |
| Travel and Lodging | $15,006 | 32 | 5.0% |
| Food and Beverage | $9,233 | 212 | 3.1% |
| Honoraria | $4,600 | 4 | 1.5% |
| Education | $229.05 | 13 | 0.1% |
Payments by Type
General
$207,518
332 transactions
Research
$89,940
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $90,707 | 77 | $0 (2024) |
| Celgene Corporation | $87,547 | 11 | $0 (2019) |
| ADC Therapeutics America, Inc. | $46,039 | 28 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $18,067 | 54 | $0 (2023) |
| Lilly USA, LLC | $12,133 | 27 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $10,580 | 7 | $0 (2023) |
| Genentech, Inc. | $5,929 | 3 | $0 (2023) |
| BeiGene USA, Inc. | $5,358 | 9 | $0 (2024) |
| MorphoSys, US Inc. | $4,345 | 2 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $4,048 | 8 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $20,345 | 25 | Genentech USA, Inc. ($8,483) |
| 2023 | $32,590 | 36 | ADC Therapeutics America, Inc. ($10,795) |
| 2022 | $32,175 | 34 | ADC Therapeutics America, Inc. ($24,569) |
| 2021 | $28,357 | 17 | Genentech USA, Inc. ($10,715) |
| 2020 | $27,661 | 29 | Genentech USA, Inc. ($9,643) |
| 2019 | $21,205 | 54 | Genentech USA, Inc. ($15,833) |
| 2018 | $61,772 | 54 | Celgene Corporation ($45,808) |
| 2017 | $73,353 | 98 | Celgene Corporation ($39,533) |
All Payment Transactions
347 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $764.68 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKINS LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $381.08 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKINS LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA | ||||||
| 11/22/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $19.04 | General |
| Category: Genetically Defined Disease | ||||||
| 11/14/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $105.58 | General |
| Category: HORMONE THERAPY | ||||||
| 10/23/2024 | ADC Therapeutics America, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,550.00 | General |
| 10/21/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $2.09 | General |
| Category: Oncology | ||||||
| 09/12/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $122.31 | General |
| Category: ONCOLOGY | ||||||
| 09/04/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,250.00 | General |
| Category: Oncology | ||||||
| 06/12/2024 | Genentech USA, Inc. | Polivy (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,040.00 | General |
| Category: BioOncology | ||||||
| 06/12/2024 | Genentech USA, Inc. | Polivy (Biological) | Travel and Lodging | Cash or cash equivalent | $124.62 | General |
| Category: BioOncology | ||||||
| 06/12/2024 | Genentech USA, Inc. | Polivy (Biological) | Food and Beverage | In-kind items and services | $118.80 | General |
| Category: BioOncology | ||||||
| 05/15/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $28.60 | General |
| Category: Oncology | ||||||
| 05/14/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $5.05 | General |
| Category: Oncology | ||||||
| 05/09/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $14.73 | General |
| Category: ONCOLOGY | ||||||
| 05/08/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $20.13 | General |
| Category: NONE | ||||||
| 04/04/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| Category: Oncology | ||||||
| 03/05/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: Oncology | ||||||
| 03/05/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,575.00 | General |
| Category: Oncology | ||||||
| 02/29/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Food and Beverage | Cash or cash equivalent | $102.90 | General |
| Category: Oncology | ||||||
| 02/23/2024 | Genentech USA, Inc. | Polivy (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,040.00 | General |
| Category: BioOncology | ||||||
| 02/23/2024 | Genentech USA, Inc. | Polivy (Biological) | Travel and Lodging | Cash or cash equivalent | $159.38 | General |
| Category: BioOncology | ||||||
| 02/16/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $26.70 | General |
| Category: ONCOLOGY | ||||||
| 01/30/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $21.97 | General |
| Category: Oncology | ||||||
| 01/26/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,406.25 | General |
| Category: Oncology | ||||||
| 01/23/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $16.29 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CC-5013-NHL-008 - A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicu | Celgene Corporation | $44,248 | 1 |
| CC-5013-NHL-008 | Celgene Corporation | $39,494 | 1 |
| A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) (CC-5013-NHL-008) | Celgene Corporation | $2,140 | 1 |
| CC-122-DLBCL-001 - A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | Celgene Corporation | $1,524 | 1 |
| AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKINS LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA | F. Hoffmann-La Roche AG | $1,146 | 2 |
| PCYC-1141-CA | Pharmacyclics LLC, An AbbVie Company | $907.87 | 8 |
| Early real-world first-line treatment with venetoclax plus HMAs versus HMA monotherapy among patients with AML in a predominately US community setting | F. Hoffmann-La Roche AG | $480.40 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 38 | 2,444 | 115,008 | $19.7M | $3.5M |
| 2022 | 41 | 2,650 | 128,384 | $19.0M | $3.2M |
| 2021 | 42 | 2,306 | 110,599 | $14.1M | $2.3M |
| 2020 | 42 | 1,978 | 120,686 | $6.9M | $2.5M |
Total Patients
9,378
Total Services
474,677
Medicare Billing
$11.5M
Procedure Codes
163
All Medicare Procedures & Services
163 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 22 | 36,800 | $7.8M | $1.6M | 20.2% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 19 | 32,220 | $6.5M | $1.2M | 18.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 39 | 10,380 | $994,740 | $192,894 | 19.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 611 | 1,426 | $1.2M | $144,752 | 11.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 173 | 520 | $499,200 | $76,778 | 15.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 81 | 481 | $512,018 | $57,522 | 11.2% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 15 | 18,700 | $374,000 | $43,755 | 11.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 68 | 212 | $144,160 | $21,105 | 14.6% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 33 | 277 | $125,053 | $18,477 | 14.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 100 | 100 | $136,000 | $17,998 | 13.2% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 18 | 105 | $423,990 | $13,530 | 3.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 115 | 142 | $72,136 | $9,453 | 13.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 53 | 546 | $133,770 | $7,708 | 5.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 272 | 791 | $45,878 | $6,017 | 13.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 39 | 101 | $39,185 | $5,895 | 15.0% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 22 | 92 | $57,040 | $5,450 | 9.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 241 | 633 | $15,825 | $5,317 | 33.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 26 | 67 | $31,490 | $4,328 | 13.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 71 | 278 | $33,897 | $3,397 | 10.0% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 19 | 112 | $53,200 | $2,976 | 5.6% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 20 | 87 | $24,555 | $2,621 | 10.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 16 | 103 | $56,650 | $2,595 | 4.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $17,360 | $2,070 | 11.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 11 | $14,520 | $1,606 | 11.1% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 28 | 1,430 | $135,850 | $1,212 | 0.9% |
About Dr. Daniel Greenwald, M.D
Dr. Daniel Greenwald, M.D is a Medical Oncology healthcare provider based in Santa Barbara, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1235240987.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Greenwald, M.D has received a total of $297,458 in payments from pharmaceutical and medical device companies, with $20,345 received in 2024. These payments were reported across 347 transactions from 52 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($115,809).
As a Medicare-enrolled provider, Greenwald has provided services to 9,378 Medicare beneficiaries, totaling 474,677 services with total Medicare billing of $11.5M. Data is available for 4 years (2020–2023), covering 163 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Santa Barbara, CA
- Active Since 08/31/2006
- Last Updated 01/07/2021
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1235240987
Products in Payments
- Revlimid (Drug) $85,897
- GAZYVA (Biological) $47,135
- VYXEOS (Drug) $10,580
- Polivy (Biological) $8,483
- Lunsumio (Biological) $7,906
- VENCLEXTA (Biological) $7,767
- JAYPIRCA (Drug) $6,834
- Venclexta (Biological) $6,409
- BRUKINSA (Drug) $5,358
- Rituxan (Biological) $4,519
- MONJUVI (Drug) $4,345
- CALQUENCE (Drug) $3,996
- XPOVIO (Drug) $2,272
- Cabometyx (Drug) $2,221
- OPDIVO (Biological) $1,844
- CC-122 (Drug) $1,524
- Non-Covered Product (Drug) $1,325
- CABOMETYX (Drug) $1,225
- Ibrutinib (Drug) $907.87
- POLIVY (Biological) $350.93
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.